25. Progressive multifocal leukoencephalopathy Clinical trials / Disease details

Clinical trials : 25 / Drugs : 35 - (DrugBank : 21) / Drug target genes : 8 - Drug target pathways : 37

diseases per page:

Showing 1 to 10 of 25 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04781309 (ClinicalTrials.gov)	May 5, 2021	3/3/2021	NT-I7, a Long-Acting Recombinant IL-7 Molecule, as an Immune Reconstitution Strategy for Lymphopenia ...	A Pilot Study of NT-I7, a Long-Acting Recombinant IL-7 Molecule, as an Immune Reconstitution Strateg ...	Progressive Multifocal Leukoencephalopathy	Drug: NT-I7	National Institute of Neurological Disorders and Stroke (NINDS)	NULL	Recruiting	18 Years	N/A	All	12	Early Phase 1	United States
2	NCT04453917 (ClinicalTrials.gov)	February 23, 2021	3/6/2020	Dynamics of T Cell Expression of Immune Checkpoint Molecules in Progressive Multifocal Leukoencephal ...	Dynamics of T Cell Expression of Immune Checkpoint Molecules in Progressive Multifocal Leukoencephal ...	Progressive Multifocal Leukoencephalopathy	Biological: Collection of blood and urine;Biological: Spinal tap;Diagnostic Test: Brain MRI;Biologic ...	University Hospital, Toulouse	NULL	Recruiting	18 Years	N/A	All	15	N/A	France
3	NCT04091932 (ClinicalTrials.gov)	August 20, 2019	15/9/2019	Treatment of PD-1 Inhibitor in AIDS-associated PML	The Effect and Safety of Programmed Cell Death Protein 1 (PD-1) Inhibitor on AIDS Patients With Prog ...	Progressive Multifocal Leukoencephalopathy;AIDS	Drug: Pembrolizumab	First Affiliated Hospital of Zhejiang University	NULL	Recruiting	18 Years	65 Years	All	10	Phase 2	China
4	NCT05236777 (ClinicalTrials.gov)	January 1, 2019	2/2/2022	TOPIK Study: A Study to Report Progressive Multifocal Leukoencephalopathyand Other Serious Opportuni ...	Long-term Surveillance of Patients With Multiple Sclerosis to Report Progressive Multifocal Leukoenc ...	Multiple Sclerosis	Drug: Natalizumab	Biogen	Association for Functional Rehabilitation, Recreation and Applied Kinesiology Impulse	Recruiting	N/A	N/A	All	600		Czechia
5	NCT03399981 (ClinicalTrials.gov)	January 24, 2018	9/1/2018	Tysabri Observational Cohort Study - Multiple Sclerosis (MS) Registries	An Observational Study Utilising Data From the US Tysabri TOUCH Programme and Select EU MS Registrie ...	Progressive Multifocal Leukoencephalopathy	Biological: Tysabri	Biogen	NULL	Active, not recruiting	N/A	N/A	All	72600		United States
6	JPRN-UMIN000022151	2016/04/30	30/04/2016	The efficacy and safety of mefloquine in patients with progressive multifocal leukoencephalopathy	The efficacy and safety of mefloquine in patients with progressive multifocal leukoencephalopathy- T ...	The efficacy and safety of mefloquine in patients with progressive multifocal leukoencephalopathy	mefloquine is to be taken orally 275mg for 3days then 275mg weekly for 6 manths	Department of Neurology, Shimane University Hospital	NULL	Complete: follow-up complete	20years-old	Not applicable	Male and Female	5	Not selected	Japan
7	JPRN-UMIN000023752	2016/04/14	24/08/2016	Medication with mefloquine hydrochloride for progressive multifocal leukoencephalopathy(PML) out of ...		progressive multifocal leukoencephalopathy	Oral mefloquinehydrochloride 275mg once a day at first 3 days. Since second week, 275mg in each week ...	Nagoya City University	NULL	Complete: follow-up complete	Not applicable	Not applicable	Male and Female	1	Not applicable	Japan
8	NCT02694783 (ClinicalTrials.gov)	March 28, 2016	27/2/2016	Adoptive Cellular Immunotherapy for Progressive Multifocal LeukoencephalopathyWith Ex Vivo Generated ...	A Pilot Study of Adoptive Cellular Immunotherapy for Progressive Multifocal LeukoencephalopathyWith ...	Progressive Multifocal Leukoencephalopathy	Biological: PyVST	National Institute of Neurological Disorders and Stroke (NINDS)	NULL	Completed	18 Years	N/A	All	60	Early Phase 1	United States
9	NCT01970410 (ClinicalTrials.gov)	October 2013	22/10/2013	Sub-Study: Analysis of JCV Antibody Index in MS Patients Treated With Teriflunomide - SWITCH-JCV	Switching Relapsing Multiple Sclerosis Patients Treated With Natalizumab at Risk for Progressive Mul ...	Multiple Sclerosis	Drug: teriflunomide	Providence Health & Services	Multiple Sclerosis Center of Northeastern New York	Active, not recruiting	21 Years	60 Years	All	41	Phase 4	United States
10	EUCTR2012-000725-41-GB (EUCTR)	22/01/2013	04/09/2012	A randomized, placebo controlled, multicenter phase IIb study of human recombinant Interleukin-7 (CY ...	A randomized, placebo controlled, multicenter phase IIb study of human recombinant Interleukin-7 (CY ...	HIV-infected patients with Progressive Multifocal Leukoencephalopathy MedDRA version: 15.0;Level: PT ...	Product Name: Recombinant human interleukin-7 Product Code: CYT107 INN or Proposed INN: N/A Other descr ...	Cytheris S.A.	NULL	Not Recruiting			Female: yes Male: yes	57	Phase 2	United States;European Union;Spain;Italy;Switzerland;United Kingdom

First Previous1 2 3Next Last